flow trial semaglutide renal outcomes 2024 kidney nejm hazard ratio 0.76 FLOW- the Visual Abstract — NephJC Treatment with sodium–glucose cotransporter 2 – Semaglutides Are Poised to Remake

The cost is $100 or more less than going straight to a drug company for a name-brand drug

Liu L, Yan H, Xia MF et al (2020) Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes

2019;8(12):e012356

Retatrutide will likely still have the low chance of severe issues like: Acute pancreatitis Gallbladder problems Severe GI events Potential for Allergic reactions A warning about thyroid tumors: No cases of medullary thyroid cancer or C-cell hyperplasia were reported in retatrutide trials, but GLP-1 receptor agonists as a class carry preclinical warnings based on rodent studies

The most cited study is a randomized, double-blind pilot in sarcoidosis patients with small fiber neuropathy symptoms, published by Dahan and colleagues and indexed at PMID 23168581